Mamifol - instructions for use, doses, side effects, contraindications

Folate deficiency causes a violation of DNA synthesis in the cell, which is preparing for chromosome replication and division.The mechanism of action is due to the participation of folic acid in the form of tetrahydrofolate in the synthesis of nucleic acids and in cell division and as a coenzyme in the synthesis of purines and pyrimidines, which makes it the decisive factor in the formation of the central nervous system that develops in humans on the 15-28th day after fertilization . The conversion of 5-methyl tetrahydrofolate to tetrahydrofolate in the body can occur only as a result of the transfer of the methyl group to the homocysteine to form methionine as a result of the action of methionine synthetase. Mamifol corrects the metabolism of the essential amino acid methionine, which is broken in mothers of children with neural tube defects.

Pharmacokinetics:

Folic acid is rapidly absorbed in the jejunum, subject to reduction and methylation to 5-methyltetrahydrofolate, which is present in the portal circulation. Its bioavailability after oral administration is high and ranges from 76% to 93%. The maximum concentration in plasma is observed after 60 minutes. There is an enteric-hepatic circulation of folate, which is indispensable for maintaining homeostasis,that methyltetrahydrofolate from the liver mainly falls into bile, and again falls into the large intestine, where it is reabsorbed. Folates are largely related to plasma proteins, the liver is the main depot. Folates are excreted in the urine in the form of metabolites, 10-formyltetrahydrofolate and 5-methyltetrahydrofolate. Folates penetrate the placental barrier and are excreted in the mother's milk.

Indications:

Prevention of folic acid deficiency in women of childbearing age, at the stages of pregnancy planning, for the prevention of neural tube defects in the fetus.

Contraindications:

Hypersensitivity to the components of the drug, malignant neoplasms, deficiency of cobalamin.

Carefully:Pernicious anemia.

Dosing and Administration:

1 tablet a day for one month before the onset of pregnancy and during the first trimester of pregnancy.

The daily dose can be doubled in case of deficiency of folic acid.

The drug is taken orally before meals.

Side effects:

Allergic reactions (erythema, pruritus, skin rash). When treatment with doses exceeding the recommended,there may be violations of the gastrointestinal tract (nausea, abdominal pain, flatulence), as well as irritability and insomnia.

If you experience any side effects not described in this manual, you should inform your doctor.

Overdose:

Doses of folic acid up to 4-5 mg are well tolerated. Higher doses can cause: violations from the central nervous system and the gastrointestinal tract.

Interaction:

Mamifol should not be taken in combination with folic acid antagonists: methotrexate and sulfasalazine, as they inhibit the enzyme hydrophotoreductase.

The drug Mamifol in combination with antiepileptic drugs from the hydantoin group. (phenytoin, phenobarbital, primidon, carbamazepine or valproic acid) can reduce the effect of the latter.

Special instructions:

There is no data on the effect of Mamifol on the ability to drive and work with machinery. However, care should be taken when performing these types of work.

This drug contains lactose, this must be taken into account for patients who have difficulty absorbing glucose or galactose, patients with galactosemia or with lactase deficiency.

The drug does not have effective action to prevent neural tube defects if the drug is taken after the fourth week of pregnancy.

Patients with pernicious anemia folic acid should be taken only in combination with cyanocobalamin.

Form release / dosage:

Tablets, 0.4 mg.

Packaging:For 28 tablets in a blister of opaque PVC / aluminum. Each blister along with instructions for use in a cardboard bundle.

Storage conditions:Store at a temperature not exceeding +30 ° C. Keep out of the reach of children.

Shelf life:

3 years. Do not use after expiry date.

Terms of leave from pharmacies:Without recipe

Registration number:LS-002247

Date of registration:04.05.2010

Expiration Date:Unlimited

The owner of the registration certificate:Italfarmaco SpAItalfarmaco SpA Italy

Manufacturer: & nbsp

ITALFARMACO, S.p.A. Italy

Representation: & nbspITF, LLCITF, LLCRussia

Information update date: & nbsp28.03.2018

Illustrated instructions

Instructions

Mamifol (Mamifol)